Study Procedures and Treatments
There was a 2‐ to 4‐week single‐blind, placebo run‐in period at baseline. The run‐in period for previously treated patients was 3 to 4 weeks, during which all existing antihypertensive therapy was tapered and discontinued, and the run‐in period for previously untreated patients was 2 weeks. After the run‐in period, patients meeting the entry criteria were randomized in a 1:1:1 ratio to 8 weeks' treatment with sacubitril/valsartan 200 mg/d, sacubitril/valsartan 400 mg/d, or olmesartan 20 mg/d, taken once daily in the morning.